RE: £2.40 Dec 2613 Apr 2026 13:33
Have had a detailed read of the valuation section of Hannam's research note. In general I think they have done a good job and reflected fair discounts to arrive at their overall valuation of £1.444bn, or £2.40 a share on a fully diluted basis. A couple of errors or wrong assumptions I would point out though:
They assume that we need to spend an extra $10.9m of capex on Germany to get to 350tpa, and then again another $10.9m to expand to 700tpa. We know that this is incorrect. We have already secured the money to get to the 350tpa as part of the placing, and it wasn't $10.9m that was needed (it was £3.95m, which also covered the feasibility study for the expansion to 750tpa). The plan is also to expand to 750tpa not 700tpa, as that is the maximum we are permitted for.
On Tyseley, they have assumed that it costs us $10.9m to expand to 350tpa and that we later expand by a further 1,000tpa to 1.35tpa, and have used the Hypromag USA capital cost of $134.4m for their cost estimate for the 1ktpa expansion. We know that all we need to do to expand to 350tpa is buy out the Uni of Birmingham, as the equipment to run at 350tpa is already commissioned and operating, so that $10.9m is incorrect, and the buy out is likely to be a lot lower, with us likely having raised the money for it through the placing in any case. We also know that the expansion is to 1ktpa, not adding an extra 1ktpa, so that is incorrect. The capital costs of $134.4m are also vastly overstated imo as we have an existing site and it would be a case of adding equipment to existing operations.
So while the analysis is comprehensive and I largely agree with it, they could have done with fact checking some of their erroneous assumptions, which overstate the capex for UK and German plants and get the total production capacity wrong.